Generic Name and Formulations:
Minoxidil 2.5 mg, 10 mg; scored tabs.
Various generic manufacturers
Indications for Minoxidil:
Refractory hypertension, usually with a diuretic and β-blocker (see literature).
Initially 5 mg once daily; may increase at 3-day intervals to 10 mg/day, then 20 mg/day, then 40 mg/day (monitor closely if titrated faster). Usual range 10–40 mg/day; max 100 mg/day. If drop in diastolic pressure >30 mmHg, give in 2 divided doses.
Initially 0.2 mg/kg once daily; may increase at 3-day intervals by 50–100%. Usual range 0.25–1 mg/kg per day; max 50 mg/day.
Supervise closely. Do not use in patients with history of recurrent pericarditis, or history of recurrent or chronic pericardial effusion. Malignant hypertension. Angina. Post MI. Heart failure. Renal dysfunction. Monitor fluid and electrolyte balance, body weight, and for pericardial effusion. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid guanethidine (hospitalize until stable if used).
Pericardial effusion or tamponade, pericarditis, salt/fluid retention, cardiac failure, tachycardia, angina, hypertrichosis, rash, GI upset, ECG changes; rare: Stevens-Johnson syndrome, thromobocytopenia, leukopenia.
Formerly known under the brand names Loniten, Minodyl.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML